Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on November 16, 2018, with the earliest event reported on that date. The filing details the entry into a material definitive agreement for a public equity offering and the subsequent closing of that offering on November 21, 2018.
Key Financial Metrics
The filing reports the following financial outcomes from the equity offering:
- Gross Proceeds: $5.5 million from the sale of 4,564,400 shares of common stock, 9.65 shares of Series C preferred stock (convertible into 965,000 shares of common stock), and 2,764,700 warrants.
- Net Proceeds: Approximately $4.6 million after deducting placement agent commissions and estimated offering expenses.
- Offering Price: $1.00 per unit (one share of common stock or preferred stock plus one-half of one warrant).
- Placement Agent Fees: 8% of aggregate gross proceeds plus fees and expenses not to exceed $167,500.
- Unit Purchase Option: Issued to the placement agent for up to 276,470 units (5% of units sold) at an exercise price of $1.25 per unit.
The filing does not provide data on revenue, operating profit, cash flow from operations, margins, or existing debt levels, as this is a transaction-specific report rather than a periodic financial statement.
Material Changes
The primary material change is the increase in capitalization and cash liquidity resulting from the November 21, 2018, closing of the public offering. Additionally, the company amended its capital structure by creating Series C Convertible Preferred Stock, with a Certificate of Designation filed on November 19, 2018.
Outlook, Risks, and Contingencies
Lock-Up Agreements: The company and its officers/directors agreed to a six-month lock-up period from the offering date, restricting the sale or transfer of capital stock, with limited exceptions for compensation and contractual obligations. The placement agent retains discretion to release these securities.
Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements related to future activities and a planned spin-off, noting that actual results may differ materially due to risks and uncertainties.
Regulatory Status: The offering was conducted pursuant to a registration statement on Form S-1 declared effective on November 16, 2018.
Key Facts for Investor Verification
- Verify the actual net proceeds received versus the estimated $4.6 million after final expense reconciliation.
- Confirm the conversion terms and liquidation preferences of the newly issued Series C Preferred Stock.
- Monitor the exercise of the 276,470-unit purchase option granted to Dawson James Securities, Inc.
- Review the company's cash burn rate to assess how long the $4.6 million in net proceeds will sustain operations.
- Check for any subsequent filings regarding the "planned spin-off" mentioned in the forward-looking statements.